Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 Gross Margin % is 58.54% as of Dec. 2025, which is 12% above its 10-year median of 52.29. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 732 Biotechnology companies, BLS Pharmaceuticals ranks worse than 62.3% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BLS Pharmaceuticals had a gross margin of 58.54% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BLS Pharmaceuticals Gross Margin % Related Terms
BLS Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BLS Pharmaceuticals (ASX:BLS) has a Gross Margin % of 58.54% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on BLS Pharmaceuticals and its competitors. This is 12% above median its historical median of 52.29. Over the past decade, BLS Pharmaceuticals' Gross Margin % has ranged from 36.32 to 55.41. According to the industry distribution chart, BLS Pharmaceuticals ranks #456 out of 732 companies in the Biotechnology industry, placing it in the top 62.3%.
Is BLS Pharmaceuticals' Gross Margin % too high?
BLS Pharmaceuticals' current Gross Margin % of 58.54% is 12% above median its 10-year median of 52.29. Over the past 10 years, this metric has ranged from a low of 36.32 to a high of 55.41. The Biotechnology industry median Gross Margin % is 60.91. BLS Pharmaceuticals' value of 58.54% is 3.9% below this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #456 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Gross Margin % compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #456 out of 732 companies for Gross Margin %. This places BLS Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 60.91. BLS Pharmaceuticals' value of 58.54% is 3.9% below this benchmark. Historically, BLS Pharmaceuticals' own Gross Margin % has ranged from 36.32 to 55.41 over the past decade. While the company's 10-year median is 52.29 vs. the industry median of 60.91, BLS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Gross Margin % of 58.54% is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Gross Margin % is 58.54%, which is 12% above median its own 10-year median of 52.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current Gross Margin % is 58.54%, which is 12% above median its 10-year median of 52.29 and 3.9% below the Biotechnology industry median of 60.91. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Gross Margin % is 58.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
Gross Margin %: 58.54% (12% above median its 10-year median of 52.29)
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
Industry Position: 3.9% below the Biotechnology median (#456 of 732)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
